Met Life Investment Management, LLC Travere Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 44,711 shares of TVTX stock, worth $956,815. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44,711
Previous 41,143
8.67%
Holding current value
$956,815
Previous $575,000
35.3%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding TVTX
# of Institutions
214Shares Held
94.3MCall Options Held
1.2MPut Options Held
778K-
Black Rock Inc. New York, NY7.64MShares$164 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.36MShares$157 Million1.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.74MShares$144 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.97MShares$106 Million3.46% of portfolio
-
Macquarie Group LTD Australia, C34.26MShares$91.2 Million0.09% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.37B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...